The DYNC1LI1 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to ablate DYNC1LI1 gene function. This heterogeneous pool of edited cells provides a robust loss-of-function model for studying cytoplasmic dynein 1-dependent processes, without requiring clonal isolation. By disrupting the gene encoding the light intermediate chain of dynein, researchers can examine the consequences of impaired retrograde microtubule-based transport in a human epithelial context.
The HT29 host cell line was originally derived from a human colorectal adenocarcinoma and displays an epithelial morphology characteristic of intestinal crypt cells. HT29 cells are widely employed in cancer research, intestinal barrier studies, and investigations of epithelial?Cmesenchymal transition. Their well-characterized signaling pathways and capacity for polarization make them an ideal platform for interrogating the roles of motor proteins like dynein in both normal cellular physiology and tumorigenesis.
DYNC1LI1 functions as an essential subunit of the cytoplasmic dynein 1 motor complex, directly linking the heavy chain (DYNC1H1) to various cargos via interactions with adaptor proteins such as BICD2 and the dynactin subunit p150Glued (DCTN1). It is regulated by mitotic kinases CDK1 and PLK1 and cooperates with RAB7A to mediate trafficking of late endosomes, lysosomes, and autophagosomes. Dynein-mediated transport driven by DYNC1LI1 is critical for autophagic flux, mitotic spindle organization, and endolysosomal maturation; accordingly, disruption of DYNC1LI1 leads to defective cargo delivery, impaired organelle positioning, and cell cycle abnormalities.
In the HT29 colorectal adenocarcinoma background, DYNC1LI1 knockout is particularly relevant for dissecting the contribution of dynein-dependent transport to cancer cell biology. Colorectal cancers often exhibit altered trafficking pathways that influence proliferation, migration, and drug sensitivity. Loss of DYNC1LI1 can compromise lysosomal function and autophagy, potentially sensitizing cells to chemotherapeutic agents or starvation stress. This polyclonal knockout population thus offers a powerful tool to explore how retrograde transport defects intersect with oncogenic signaling in intestinal epithelial tumors.
Researchers can employ this knockout model in a wide range of experimental approaches, including live-cell imaging to track organelle dynamics, immunofluorescence and western blotting to assess protein distribution and expression, co-immunoprecipitation to probe dynein?Ccargo interactions, and functional assays such as migration/invasion and drug sensitivity studies. By comparing polyclonal knockout cells with parental HT29 lines, users can elucidate DYNC1LI1-dependent mechanisms in autophagy, mitosis, and endosomal trafficking. For further information, please contact Ascent Research.
